Montelukast in Modulating Exacerbations of Asthma in Children

Firestone Institute for Respiratory Health

Status and phase

Completed

Phase 4

Conditions

Asthma

Treatments

Drug: Montelukast (drug)

Study type

Interventional

Funder types

Other

Identifiers

NCT00196547

R.P. #05-2440

Details and patient eligibility

About

The purpose of the study is to determine if Montelukast added to other therapy, if any, will reduce the severity of asthma symptoms in children during the high incidence of respiratory viral infections that occur in children in the post Labor Day school return period.

Full description

Between 1990- and 2003, we identified in Ontario, and subsequently across Canada, a striking increase in hospital admissions for asthma in children occurring predictably in the third week of September every year.1 In 2000 we undertook a retrospective case-control study comparing the clinical characteristics of children using local emergency rooms for asthma in September, with those of children presenting during the non-epidemic months of July-August. Based on that pilot study of 169 children, we developed a larger prospective case-control study of clinical and biological characteristics of children recruited as they presented to an emergency room for asthma during September 2001. The control group for this study were children recruited from the community who had symptomatic asthma but did not have a September exacerbation requiring emergency room utilization. We identified the presence of rhinovirus in the majority of children attending an ER with acute asthma, and also found rhinovirus in a substantial proportion of the community based controls. We also found a highly significant difference in use of medications for asthma, with the ER cases being much less likely to be receiving adequate anti-inflammatory medication. In September 2004 we conducted a pilot randomized controlled blinded clinical trial of the efficacy of montelukast in reducing morbidity caused by asthma exacerbations associated with respiratory viral infections (RVI) in children aged 2 to 14. We found a highly significant reduction in reported symptom free days in the montelukast group. The current study is a randomized placebo-controlled trial of montelukast, during September 2005 to confirm the results of our pilot study and to examine the effectiveness of montelukast in reducing asthma morbidity during RVIs in different age and sex groups with a range of risk of exacerbations. We also wish to compare the effectiveness of montelukast to placebo in reducing asthma morbidity during RVIs between groups of children concurrently taking no or other classes of asthma control medications.

Sex

All

Ages

2 to 14 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Children aged 2-14 years inclusive
Doctor-diagnosed asthma
Needing a beta-agonist inhaler at least once weekly on average for symptom relief
At least one day lost from school in the past year, or significantly limited activity, because of asthma
A history of asthma exacerbations associated with apparent respiratory viral infections
Parent or guardian who is willing to provide informed consent
Willing to give assent

Exclusion criteria

Non-English speaking
Unable to understand purpose of study and give consent
Concomitant respiratory or other major illness e.g. cystic fibrosis, cardiac disease
Currently using montelukast or other leukotriene receptor antagonist
Using regular oral corticosteroid
An asthma exacerbation requiring medical intervention during August 2005